KA
KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
$27.00 +0.07% (+$0.02)
Market Cap $1.44B
P/E Ratio -
Div. Yield -
ROE 561.29%
Bulios Fair Price
$28.81
6.7% upside
Current Price
$27
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KALV is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
0 /100
Expensive P/S 104.99x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 7.04%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 18.24%
Net margin 1,542.07%
Op. margin 1,559.72%
Quality
0 /100
Poor ROIC 76.05%
ROE 561.29%
ROA 62.96%
Debt
71 /100
Low Current ratio 5.58x
Int. coverage -15.66x
Net debt/EBITDA 0.36x
Stability
51 /100
Moderate Beta -0.29x
EPS volatility 24.92%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KALV
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Benjamin L. Palleiko
Employees
275
Headquarters
Framingham
Upcoming events
03 DEC
Earnings
Upcoming earnings report